Screener
Krystal Biotech, Inc. KRYS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued rebates | 12,685 | 10,601 |
| Accrued expenses and other current liabilities | (6,312) | 3,695 |
| Accrued legal settlement | — | (31,250) |
| Net cash provided by operating activities | 80,382 | 30,969 |
| Investing Activities | ||
| Proceeds from disposal of assets | — | 435 |
| Purchases of property and equipment | (7,148) | (6,204) |
| Purchases of investments | (160,033) | (137,806) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s operating cash flow?
- Krystal Biotech, Inc. (KRYS) reported operating cash flow of $80.38M in Q1 2026.
- How has Krystal Biotech, Inc.'s operating cash flow changed year-over-year?
- Krystal Biotech, Inc.'s operating cash flow increased by 159.6% year-over-year, from $30.97M to $80.38M.
- What is the long-term trend for Krystal Biotech, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s operating cash flow has grown at a 43.1% compound annual growth rate (CAGR), from -$47.94M to $200.87M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Krystal Biotech, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude